Fibroblast Growth Factor 23 as a Prognostic Biomarker in Post‐Myocardial Infarction Outcomes: Influence of Renal Function and Its Modulation by Klotho
FGF23 represents a promising biomarker for mortality and cardiac dysfunction in patients with MI. Although Klotho does not appear to be a reliable predictor of mortality after MI, its cardioprotective properties suggest a role in modulating FGF23-driven metabolic, structural, and proliferative processes in the myocardium.
Authors
- Gema Ruiz‐Hurtado (ORCID: https://orcid.org/0000-0003-3482-0915)
- Elisa Mercado‐García (ORCID: https://orcid.org/0009-0009-7033-8166)
- José Alberto Navarro‐García (ORCID: https://orcid.org/0000-0002-0317-4888)
- Marta Gil‐Fernández (ORCID: https://orcid.org/0000-0001-7219-202X)
- G. Barderas María
- Elena Rodríguez‐Sánchez (ORCID: https://orcid.org/0000-0002-5020-949X)
- Andrea Matutano (ORCID: https://orcid.org/0000-0003-3202-9345)
- María Fernández‐Velasco
- Laura González‐Lafuente
- Laura Mourino‐Álvarez
- Ana Blasco
- Alberto Pérez‐Gómez
- Nerea Corbacho‐Alonso
- Marina Polo‐Salguero
- Juan Antonio López
- Daniel González‐Moreno
- Sara Vázquez‐Sánchez
Institutions
- Hospital Universitario La Paz (ES)
- Royal Institution of Chartered Surveyors (GB)
- Instituto de Salud Carlos III (ES)
- Hospital Universitario 12 De Octubre (ES)
- Hospital Universitario Puerta de Hierro Majadahonda (ES)
- Servicio de Salud de Castilla La Mancha (ES)
- Hospital Nacional de Parapléjicos (ES)
- Universidad Autónoma de Madrid (ES)
Publication Details
- Journal
- Journal of the American Heart Association
- Published
- 2026-02-12
- DOI
- https://doi.org/10.1161/jaha.125.045175
- Primary Topic
- Parathyroid Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00